Organogenesis Inc. is a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company’s mission is to provide integrated healing solutions that substantially improve medical outcomes and the lives of patients while lowering the overall cost of care.
Organogenesis' versatile product portfolio is designed to treat a variety of patients with repair and regenerative needs across the continuum of care.
Organogenesis Inc. was originally founded in 1985 as a spin-off of technology developed at the Massachusetts Institute of Technology (MIT). In 2017, Organogenesis acquired NuTech Medical, which further expanded our wound care portfolio and introduced product solutions for the surgical and sports medicine markets.
Today, Organogenesis has approximately 600 employees worldwide and is led by a management team of talented individuals with more than 100 years of collective regenerative medicine experience.
1998: FDA approves Apligraf® for the treatment of venous leg ulcers.
2000: FDA approves Apligraf® for the treatment of diabetic foot ulcers.
2004: Launch of full USA sales and marketing organization.
2006: European office established in Switzerland.
2014: Acquires Dermagraft® for treatment of chronic diabetic foot ulcers.
2015: Launches new PuraPly® product line.
2017: Acquires NuTech Medical and expands product portfolio to include Surgical and Sports Medicine.